Bioxcel Therapeutics BTAI 深 滬
等待開盤 08-15 09:30:00 美东时间
4.75
-0.850
-15.18%
華盛通- 最 高6.23
- 今 開5.01
- 成交量 831.35万股
- 最 低 4.61
- 昨 收 5.60
- 總市值 2876.60万
- 52周最高 13.3616
- 市盈率 靜 --
- 換手率 137.28%
- 52周最低 1.17
- 委 比 46.43%
- 總股本 605.60万
- 歷史最高 1144.00
- 量 比 0.27
- 振 幅 28.93%
- 歷史最低 2.56
- 每 手 1
- 風險率 3.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多3 Supercharged Stocks Flashing Strong Momentum Signals
Here's a look at some standout momentum movers that are just starting to pick up steam.
08-14 00:33
BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series
BioXcel Therapeutics, a biopharmaceutical company using AI in neuroscience drug development, announced that its CEO, Vimal Mehta, will participate in a virtual fireside chat on August 14, 2025, at 1:00 p.m. ET as part of H.C. Wainwright's "HCW@Home" series. The company employs a drug re-innovation approach combining big data and machine learning to identify new therapeutic indications.
08-13 11:00
BioXcel Therapeutics (BTAI) Stock Is Extremely Volatile Today: What's Going On?
Shares of BioXcel Therapeutics are trading sharply lower Tuesday morning. The company announced its financial results for Q2.
08-13 01:02
BioXcel Therapeutics Q2 EPS $(2.45) Beats $(3.28) Estimate, Sales $120.00K Miss $283.33K Estimate
BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(2.45) per share which beat the analyst consensus estimate of $(3.28) by 25.24 percent. This is a 27.08 percent increase over losses of $(3.36) per share
08-12 19:56
BioXcel Therapeutics Raises $30.4M, Meets Financing Covenant
Bioxcel Therapeutics ( ($BTAI) ) just unveiled an update. BioXcel Therapeutics ...
08-12 05:32
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Equillium (NASDAQ:EQ) shares moved upwards by 98.9% to $0.98 during Mo...
08-12 01:06
BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference
BioXcel Therapeutics, Inc. announced that its CEO, Vimal Mehta, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, at 12 p.m. ET. The event will be webcast and available for replay for 90 days. The company focuses on developing medicines in neuroscience and immuno-oncology using artificial intelligence.
08-11 11:00
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
BioAtla reports progress on its clinical programs, including the Phase 1 dose-escalation study of BA3182 (a CAB-EpCAM x CAB-CD3 bispecific T-cell engager) and the Fast Track Designated Ozuriftamab vedotin (Oz-V) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). BA3182 has shown promising tumor reductions and prolonged progression-free intervals, with an expected Phase 1 data readout in the second half ...
08-07 20:05
BioXcel Study Highlights Dexmedetomidine’s Potential Benefits
Bioxcel Therapeutics ( ($BTAI) ) just unveiled an announcement. On August 6, 20...
08-06 19:48
BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies
BioXcel Therapeutics announced promising results for BXCL501, a drug developed from dexmedetomidine, showing significant reduction in stress-induced behaviors and potential for treating chronic psychiatric disorders. Already FDA-approved as IGALMI for acute agitation in bipolar disorder and schizophrenia, BXCL501 is being studied for daily dosing in conditions like opioid withdrawal, acute stress disorder, and alcohol use disorder in PTSD patient...
08-06 11:00
